COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026 -
-
COMMUNIQUÉ RÉGLEMENTÉ
Mersen : Performance résiliente en 2025, retour attendu de la croissance en 2026
Mersen affiche une performance résiliente en 2025 avec un chiffre d'affaires de 1 186 M€, une marge d'EBITDA maintenue à 16% et un retour anticipé au free cash-flow positif. Objectifs 2026 : croissance organique et marge EBITDA autour de 16% -
COMMUNIQUÉ DE PRESSE
2025 annual results: strong improvement in financial earnings and cash-flows
Exail Technologies achieved significant financial growth in 2025 with record order intake of €844 million (+87%), revenue growth of +28%, and strengthened balance sheet post fundraising of €300 million. Operational milestones include delivering mine countermeasures to navies and increasing production capacity for navigation systems -
COMMUNIQUÉ DE PRESSE
Résultats annuels 2025 : forte amélioration des résultats et des flux de trésorerie
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
Sanofi's venglustat receives innovative therapy designation in the US for Gaucher disease type 3. Positive results from the LEAP2MONO study reinforce its potential as a treatment option -
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
Heidelberg Pharma to receive milestone payment from partner Huadong for clinical study with HDP-101 in China. First patient dosed in Phase I study evaluating safety, tolerability, and efficacy -
COMMUNIQUÉ DE PRESSE
SMG reports strong 2025 results with significant margin uplift
SMG Swiss Marketplace Group reports strong 2025 financial results with revenue of CHF 332.0 million and Adjusted EBITDA up to CHF 180.2 million, lifting margin to 54.3%. Continues innovating with AI for user experience and efficiency
